LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 13, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the
appointment of Dr. Sumant Ramachandra as President, Research and
Development.
Prior to Synta, Dr. Ramachandra was Senior Vice President, Research and
Development (R&D), Regulatory and Medical Affairs, and Chief Scientific
Officer of Hospira, a specialty pharmaceuticals and medical device
company. At Hospira, Dr. Ramachandra led a 1,200 person R&D organization
and was recognized for his achievements and contributions as a
healthcare leader in PharmaVoice’s “100 of the Most Inspiring People,”
Diversity MBA’s “Top 100 Under 50 Diverse Executive Leaders,” and
Chicago Business’ “Crain’s 40-under-40.”
Prior to joining Hospira in 2008, Dr. Ramachandra was Vice President and
oncology portfolio therapeutic area leader at Merck & Co. (formerly
Schering-Plough), and prior to Merck/Schering-Plough he was therapeutic
area head for medical oncology at Pfizer (formerly Pharmacia). At these
companies, Dr. Ramachandra drove the development, regulatory approval,
and market expansion studies for numerous oncology products.
“Sumant brings a broad range of development and regulatory leadership
experience, as well as a unique perspective having led both oncology
development at large pharmaceutical companies, and the broader range of
R&D functions at a large, global specialty pharma company,” said Safi
Bahcall, President and CEO, Synta. “Sumant’s experiences with a wide
range of drugs, manufacturers, pharma companies, payors, providers, and
regulatory agencies will enhance our ability to realize the full
potential of our product pipeline to benefit patients.”
“The programs at Synta can change the treatment of many types of
cancers,” said Dr. Ramachandra. “In addition, Synta’s culture of
innovation, collaboration, and commitment to speed and excellence in
execution are exciting and critical to success in our industry. I am
very much looking forward to being part of the Synta team and
contributing to bringing these new drugs to cancer patients.”
Dr. Ramachandra received a bachelor's degree in biochemistry from
Rutgers University, and M.D. and Ph.D. degrees from the University of
Medicine and Dentistry-New Jersey Medical School. He conducted his
residency at the Harvard-affiliated Massachusetts General Hospital
(MGH). Dr. Ramachandra also earned a master's of business administration
from the Wharton Business School at the University of Pennsylvania.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as "will", "would",
"should", "expects", "anticipates", "intends", "plans", "believes",
"may", "estimates", "predicts", "projects", or similar expressions
intended to identify forward-looking statements. Such statements,
including statements relating to the timing, developments and progress
of our clinical and preclinical programs, reflect our current views with
respect to future events and are based on assumptions and subject to
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements, including those described in "Risk Factors" of our Form 10-K
for the year ended December 31, 2011 as filed with the Securities and
Exchange Commission. Synta undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future
events or otherwise, except as required by law.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213